Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries

Published:December 14, 2015DOI:https://doi.org/10.1016/j.ijcard.2015.12.015

      Abstract

      Aims

      To conduct a prospective, individual participant data (IPD) meta-analysis of randomised controlled trials comparing a polypill-based approach with usual care in high risk individuals.

      Methods and results

      Three trials comparing polypill-based care with usual care in individuals with CVD or high calculated cardiovascular risk contributed IPD. Primary outcomes were self-reported adherence to combination therapy (anti-platelet, statin and ≥two blood pressure (BP) lowering agents), and difference in mean systolic BP (SBP) and LDL-cholesterol at 12 months. Analyses used random effects models. Among 3140 patients from Australia, England, India, Ireland, New Zealand and The Netherlands (75% male, mean age 62 years), median follow-up was 15 months. At baseline, 84%, 87% and 61% respectively were taking a statin, anti-platelet agent and at least two BP lowering agents. At 12 months, compared to usual care, participants in the polypill arm had higher adherence to combination therapy (80% vs. 50%, RR 1.58; 95% CI, 1.32 to 1.90; p < 0.001), lower SBP (−2.5 mmHg; 95% CI, −4.5 to −0.4; p = 0.02) and lower LDL-cholesterol (−0.1 mmol/L; 95% CI, −0.2 to 0.0; p = 0.04). Baseline treatment levels were a major effect modifier for adherence and SBP (p-homog <0.0001 and 0.02 respectively) with greatest improvements seen among those under-treated at baseline.

      Conclusions

      Polypill therapy significantly improved adherence, SBP and LDL-cholesterol in high risk patients compared with usual care, especially among those who were under-treated at baseline.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yusuf S.
        • Islam S.
        • Chow C.K.
        • Rangarajan S.
        • Dagenais G.
        • Diaz R.
        • et al.
        Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey.
        Lancet. 2011; 378: 1231-1243
        • Lafeber M.
        • Spiering W.
        • Singh K.
        • Guggilla R.K.
        • Patel V.
        • Webster R.
        The cardiovascular polypill in high-risk patients.
        Eur. J. Cardiovasc. Prev. Rehabil. 2011;
        • World Health Organization
        Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions.
        (Geneva)2002
        • Patel A.
        • Cass A.
        • Peiris D.
        • Usherwood T.
        • Brown A.
        • Jan S.
        • et al.
        A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
        Eur. J. Prev. Cardiol. 2014;
        • Selak V.
        • Elley C.R.
        • Bullen C.
        • Crengle S.
        • Wadham A.
        • Rafter N.
        • et al.
        Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
        BMJ. 2014; 348
        • Thom S.
        • Poulter N.
        • Field J.
        • Patel A.
        • Prabhakaran D.
        • Stanton A.
        • et al.
        Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
        JAMA. 2013; 310: 918-929
        • Castellano J.M.
        • Sanz G.
        • Penalvo J.L.
        • Bansilal S.
        • Fernandez-Ortiz A.
        • Alvarez L.
        • et al.
        A polypill strategy to improve adherence: results from FOCUS (Fixed-dose combination drug for secondary cardiovascular prevention) project.
        J. Am. Coll. Cardiol. 2014;
        • Webster R.
        • Patel A.
        • Billot L.
        • Cass A.
        • Burch C.
        • Neal B.
        • et al.
        Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE collaboration.
        Int. J. Cardiol. 2013; 170: 30-35
        • Liu H.M.
        • Patel A.
        • Brown A.
        • Eades S.
        • Hayman N.
        • Jan S.
        • et al.
        Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non-indigenous people at high cardiovascular risk.
        BMC Public Health. 2010; 10: 458
        • Selak V.
        • Elley C.R.
        • Crengle S.
        • Harwood M.
        • Doughty R.
        • Arroll B.
        • et al.
        Improving adherence using combination therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.
        Contemp. Clin. Trials. 2011; 32: 909-915
        • Thom S.
        • Field J.
        • Poulter N.
        • Patel A.
        • Prabhakaran D.
        • Stanton A.
        • et al.
        Use of a multidrug pill in reducing cardiovascular events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
        Eur. J. Prev. Cardiol. 2012;
        • New Zealand Guidelines Group
        New Zealand Cardiovascular Guidelines Handbook: a Summary Resource for Primary Care Practitioners.
        New Zealand Guidelines Group, Wellington2005
        • World Health Organisation
        Adherence to Long-term Therapies. Evidence for Action.
        WHO, Geneva2003
        • Debray T.P.A.
        • Moons K.G.M.
        • Abo-Zaid G.M.A.
        • Koffijberg H.
        • Riley R.D.
        Individual participant data meta-analysis for a binary outcome: one-stage or two-stage?.
        PLoS ONE. 2013; 8e60650
        • Cannon C.P.
        Can the polypill save the world from heart disease?.
        Lancet. 2009; 373: 1313-1314
        • Helfand M.
        • Carson S.
        • Kelley C.
        Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final Report.
        Oregon Health & Science University, Portland (OR)2006
      1. (accessed 3rd September 2014)
        • Rodgers A.
        • Patel A.
        • Berwanger O.
        • Bots M.
        • Grimm R.
        • et al.
        • Pill Collaborative Group
        An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
        PLoS ONE. 2011; 6e19857
        • Collins R.
        • Peto R.
        • MacMahon S.
        • Hebert P.
        • Fiebach N.H.
        • Eberlein K.A.
        • et al.
        Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
        Lancet. 1990; 335 ([see comment]): 827-838
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Law M.R.
        • Morris J.K.
        • Wald N.J.
        Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
        BMJ. 2009; 338b1665
        • Antiplatelet Trialists' Collaboration
        Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
        Br. Med. J. 1994; 308: 81-106
        • Cholesterol Treatment Trialists' (CTT) Collaboration
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Soliman E.
        • Mendis S.
        • Dissanayake W.
        • Somasundaram N.
        • Gunaratne P.
        • Jayasingne I.K.
        • et al.
        A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
        Trials. 2011; 12: 3
        • Yusuf S.
        • Pais P.
        • Sigamani A.
        • Xavier D.
        • Afzal R.
        • Gao P.
        • et al.
        Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the second Indian polycap study (TIPS-2) investigators.
        Circ. Cardiovasc. Qual. Outcomes. 2012; 5: 463-471
        • Elley C.R.
        • Gupta A.K.
        • Webster R.
        • Selak V.
        • Jun M.
        • Patel A.
        • et al.
        The efficacy and tolerability of ‘polypills’: meta-analysis of randomised controlled trials.
        PLoS ONE. 2012; 7e52145-e
        • de Cates A.N.
        • Farr M.R.
        • Wright N.
        • Jarvis M.C.
        • Rees K.
        • Ebrahim S.
        • et al.
        Fixed-dose combination therapy for the prevention of cardiovascular disease.
        Cochrane Database Syst. Rev. 2014; 4CD009868
        • Yusuf S.
        • Islam S.
        • Chow C.K.
        • Rangarajan S.
        • Dagenais G.
        • Diaz R.
        • et al.
        Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey.
        Lancet. 2011; 378: 1231-1243
        • World Health Organisation
        Global Action Plan for the Prevention and Control of Noncommunicable Diseases.
        World Health Organization, Geneva2013